Skip to main content

Table 1 Tumor characteristics of identified PALB2 c.1592delT mutation carriers

From: Evaluation of the need for routine clinical testing of PALB2 c.1592delT mutation in BRCA negative Northern Finnish breast cancer families

Family id

Cancer (age)

Histology

TNM

ER/PR status

Grade

Her2

p53

Ki67

Other cancer cases in the family

Fam A

Br(63)

Ductal

T2N0M0

ER pos/PR pos

2

Neg

Neg

2

Br(44), Br(73), Cancer

Fam B

Br(43)

Ductal

TisN0M0

ER pos/PR pos

1

Neg

NA

0

Br(30), Br(53), Br(65), Br, Br, Lung, Ov(60), Panc, Sarc, Skin, Sto

Fam C

Br(39)

Ductal

T2N0M0

ER pos/PR pos

3

NA

Neg

2

Br(67), Br(68), Ov(71), Panc, Ut(36), Ut

  1. ER, Estrogen receptor; PR, Progesterone receptor; Her2, Human epidermal growth factor receptor 2; p53, Tumor protein 53; Ki67, Antigen Ki67; Br, Breast; Cancer, Cancer of unknown type for which no pathology reports were available; Ov, Ovarian; Panc, Pancreatic; Sarc, Sarcoma; Sto, Stomach; Ut, Uterus; NA, Not available.